Most telehealth GLP-1 programs require a BMI of 27 or higher with a weight-related health condition, or a BMI of 30 or higher without comorbidities, consistent with FDA labeling for chronic weight management
[For example,] a patient whose main issue is inflammation might benefit more from the anti-inflammatory effect of the drug than a patient whose Crohn's disease has led to strictures, [or] a narrowing of the intestine. The Takeaway GLP-1s decrease inflammation throughout the body, and may improve Crohns disease outcomes
It's the acronym for Butylated Hydroxy Toluene
As is often the case, a failure in science, in reality, did not invalidate a strong GLP-1 hypothesis, rather it improves, or refines, it for follow up investigations
1 The reason theres no direct interaction comes down to how each drug is processed by your body
Both have been shown to support significant weight loss